Provided by Tiger Fintech (Singapore) Pte. Ltd.

bluebird bio

4.09
-0.2500-5.76%
Post-market: 4.090.00000.00%18:37 EDT
Volume:156.42K
Turnover:658.52K
Market Cap:40.04M
PE:-0.16
High:4.57
Open:4.41
Low:4.08
Close:4.34
Loading ...

Bluebird Bio announces 1-for-20 reverse stock split

TIPRANKS
·
05 Dec 2024

bluebird bio Announces 1-for-20 Reverse Stock Split

THOMSON REUTERS
·
05 Dec 2024

bluebird bio Announces 1-for-20 Reverse Stock Split

Business Wire
·
05 Dec 2024

Bluebird Bio participates in CMMI Cell and Gene Therapy Access Model

TIPRANKS
·
04 Dec 2024

CMS enters agreement with Vertex, bluebird to improve access to gene therapies

Reuters
·
04 Dec 2024

BRIEF-bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model

Reuters
·
04 Dec 2024

bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (Cmmi) Cell and Gene Therapy Access Model

THOMSON REUTERS
·
04 Dec 2024

bluebird bio Inc - States Can Opt in to Agreement Until February 28, 2025

THOMSON REUTERS
·
04 Dec 2024

CMS: 2 Drug Manufacturers With FDA-Approved Gene Therapies for Sickle Cell Disease to Participate in Cell & Gene Therapy Access Model With CMS

THOMSON REUTERS
·
04 Dec 2024

CMS: Cell & Gene Therapy Access Model Launches in Jan 2025, States May Choose to Begin Participation Anytime Between Jan 2025 & Jan 2026

THOMSON REUTERS
·
04 Dec 2024

FDA Probes Potential Life-Threatening Blood Cancer Risks Linked To Bluebird Bio's Skysona Gene Therapy

Benzinga
·
29 Nov 2024

Press Release: BLUE MOON METALS TO ACQUIRE TWO NORWEGIAN BROWNFIELD COPPER DISTRICTS FOR US$67.3M AND TO COMPLETE A MINIMUM C$30 MILLION EQUITY FINANCING

Dow Jones
·
28 Nov 2024

bluebird bio Shares Down 1.3% at $0.36 After FDA Probes Cancer Risks of Co's Gene Therapy

THOMSON REUTERS
·
28 Nov 2024

BUZZ-Bluebird falls as FDA weighs cancer risks of co's gene therapy

Reuters
·
28 Nov 2024

FDA probes blood cancer risk from bluebird's gene therapy, weighs regulatory action

Reuters
·
28 Nov 2024

FDA investigates risk of blood cancers from bluebird bio's gene therapy

Reuters
·
28 Nov 2024

BRIEF-FDA Investigating Serious Risk Of Hematologic Malignancy Following Skysona (Elivaldogene Autotemcel)

Reuters
·
28 Nov 2024

FDA Investigating Serious Risk of Hematologic Malignancy Following Skysona (Elivaldogene Autotemcel)

THOMSON REUTERS
·
28 Nov 2024

WYNNEFIELD GROUP SENDS DEFINITIVE PROXY MATERIALS TO TECHPRECISION STOCKHOLDERS, INCLUDING A BLUE PROXY CARD AND A LETTER SEEKING TO HOLD MEMBERS OF THE BOARD ACCOUNTABLE FOR YEARS OF POOR OPERATING RESULTS, POOR PERFORMANCE AND A SERIES OF COSTLY STRATEGIC MISSTEPS

PR Newswire
·
25 Nov 2024

Analysts Offer Insights on Healthcare Companies: Benitec Biopharma (BNTC), Bluebird Bio (BLUE) and AC Immune SA (ACIU)

TIPRANKS
·
19 Nov 2024